结构治疗报告了其口服药物aleniglipron的减肥结果,44周平均减肥高达16. 3%,56周持续进展,促使计划进行第三阶段试验和市场积极反应. Structure Therapeutics reports promising weight-loss results for its oral drug aleniglipron, with up to 16.3% average loss over 44 weeks and ongoing progress through 56 weeks, prompting plans for Phase 3 trials and a positive market reaction.

结构治疗报告了其口服肥胖药物aleniglipron的2期试验结果,显示44周平均体重减轻高达16. 3%,在56周持续体重减轻没有高峰. Structure Therapeutics reported positive Phase 2 trial results for its oral obesity drug aleniglipron, showing up to 16.3% average weight loss over 44 weeks, with no plateau in continued weight loss through 56 weeks. 该药物表现出很强的耐受性和低停用率,加上低开始剂量的支持。 The drug demonstrated strong tolerability and low discontinuation rates, supported by a low starting dose. 该公司计划在2026年第二季度召开B型FDA会议,并预计今年晚些时候开始第三阶段试验. The company plans a Type B FDA meeting in Q2 2026 and expects to begin Phase 3 trials later in the year. 在市场前贸易中,股票增加了14%以上。 Shares rose over 14% in pre-market trading.